Holen Sie sich die Stockscreener-App
31.37
1.00%
0.31
Handel nachbörslich:
31.37
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex closes $345 million stock offering By Investing.com - Investing.com Canada
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics Completes $345 Million Public Offering of Common Stock - Quiver Quantitative
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - marketscreener.com
Celldex sells nearly 11.9M shares, raises $345M in stock deal - stocktitan.net
Celldex Therapeutics announces public offering of common stock - MSN
Celldex Therapeutics, Inc. (CLDX) Options Chain - Yahoo! Finance Canada
JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Announces Pricing of $300 Million Public Offering of Common Stock - Sahm
Celldex Therapeutics stock falls on equity offering - Investing.com
Celldex Therapeutics stock falls on equity offering By Investing.com - Investing.com Canada
Celldex prices $300 million stock offering at $29 per share By Investing.com - Investing.com Australia
Celldex Therapeutics offers 10,345,000 shares of common stockSEC filing - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) raises ~$282M net in $29 follow-on offering - stocktitan.net
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Celldex shares plunge after dumping $300 million stock deal - gurufocus.com
Celldex Announces Major Underwritten Public Equity Offering - TipRanks
Celldex Therapeutics Inc (TCE2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering - TradingView
Celldex (NASDAQ: CLDX) raises $300M in new common stock sale - stocktitan.net
Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? - Yahoo Finance
Celldex launches public offering of common stock By Investing.com - Investing.com South Africa
Celldex Therapeutics Inc (TCE2.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Announces $300 Million Public Stock Offering - National Today
Celldex Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Celldex prices $300 million stock offering at $29 per share - Investing.com
Celldex lines up $300M for drug launch prep and pipeline work - stocktitan.net
Celldex announces pricing of $300 million public offering of common stock - marketscreener.com
Celldex announces proposed public offering of common stock - marketscreener.com
Celldex Announces Proposed Public Offering of Common Stock - bitget.com
Celldex Therapeutics (NASDAQ: CLDX) files prospectus supplement for common stock offering - Stock Titan
Celldex turns to stock sale to fund drug launch prep and pipeline - stocktitan.net
CLDX PE Ratio & Valuation, Is CLDX Overvalued - Intellectia AI
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving AverageShould You Sell? - marketbeat.com
Earnings Report: What makes Celldex Therapeutics Inc stock attractive today2026 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Portfolio Recap: Does Celldex Therapeutics Inc stock benefit from AI growth2026 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation As Shares Show Renewed Momentum - simplywall.st
Will Celldex Therapeutics Inc stock hit new highs in YEARQuarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Celldex Therapeutics presents positive phase 2 data for barzolvolimab in CSU, ColdU, and SD - marketscreener.com
Celldex reports quality of life gains in urticaria trials - Investing.com
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 - Yahoo Finance
Celldex reports quality of life gains in urticaria trials By Investing.com - Investing.com Canada
Vanguard discloses 0 ownership in Celldex (CLDX) after realignment - stocktitan.net
Will Celldex Therapeutics Inc benefit from government policy2026 Risk Factors & High Accuracy Buy Signal Tips - baoquankhu1.vn
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):